Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169949 · ClinicalTrials.gov registry record · NA
Aripiprazole Treatment of the Prodrome
A NA study, sponsored by Northwell Health.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00169949 is a NA study that was terminated before completion, run by Northwell Health. The registered enrollment target is 30 participants.
The verdict
NCT00169949, a NA study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00169949
The ClinicalTrials.gov registry entry for NCT00169949 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00169949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00169949 about?
NCT00169949 is a clinical study titled "Aripiprazole Treatment of the Prodrome". The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychot...
What is the current status of trial NCT00169949?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2004-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00169949?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00169949?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.